Zymedi
The startup develops a therapeutics platform that targets aminoacyl-tRNA synthetases (ARSs) to address pulmonary arterial hypertension and liver fibrosis. This approach enables faster initiation of treatment, leading to improved patient outcomes.
Traction –/10
Incheon, South Korea · HQ
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$31.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a therapeutics platform that targets aminoacyl-tRNA synthetases (ARSs) to address pulmonary arterial hypertension and liver fibrosis. This approach enables faster initiation of treatment, leading to improved patient outcomes.